Suppression of STAT3 and HIF-1 Alpha mediates Anti-Angiogenic activity of Betulinic acid in Hypoxic PC-3 prostate cancer cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Shin, Jimin ^a   Lee, Hyo Jeong ^a   Jung, Deok Beom ^a   Jung, Ji Hoon ^a   Lee, Hyo Jung ^a   Lee, Eun Ok ^a   Lee, Seok Geun ^a   Shim, Beom Sang ^a   Choi, Seung Hoon ^a   Ko, Seong Gyu ^a   Ahn, Kwang Seok ^a   Jeong, Soo Jin ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; STAT3 PROTEIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HIF1A PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TRITERPENE; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL DEATH; CELL HYPOXIA; CHEMISTRY; DRUG EFFECT; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; PROTEIN BINDING; TUMOR CELL LINE; VASCULARIZATION;

BETULA PENDULA;

ANGIOGENESIS INHIBITORS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959606207     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021492     Document Type: Article

References (40)

1. Bowman T, Garcia R, Turkson J, Jove R, (2000) STATs in oncogenesis. Oncogene 19: 2474-2488.
2. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, et al. (2006) Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151-169.
3. Yee Koh M, Spivak-Kroizman TR, Powis G, (2008) HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 33: 526-534.
4. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, et al. (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. Faseb J 19: 1296-1298.
5. Jung JE, Kim HS, Lee CS, Shin YJ, Kim YN, et al. (2008) STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med 40: 479-485.
6. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, et al. (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051.
7. Mullauer FB, Kessler JH, Medema JP, (2010) Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 21: 215-227.
8. Fulda S, (2009) Betulinic acid: a natural product with anticancer activity. Mol Nutr Food Res 53: 140-146.
9. Mukherjee PK, Saha K, Das J, Pal M, Saha BP, (1997) Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera. Planta Med 63: 367-369.
10. De Clercq E, (1995) Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 8: 200-239.
11. Chadalapaka G, Jutooru I, Burghardt R, Safe S, (2010) Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8: 739-750.
12. Eichenmuller M, Hemmerlein B, von Schweinitz D, Kappler R, (2010) Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Br J Cancer 103: 43-51.
13. Pandey MK, Sung B, Aggarwal BB, (2010) Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 127: 282-292.
14. Rabi T, Shukla S, Gupta S, (2008) Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells. Mol Carcinog 47: 964-973.
15. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
16. Smith TG, Robbins PA, Ratcliffe PJ, (2008) The human side of hypoxia-inducible factor. Br J Haematol 141: 325-334.
17. Niu G, Briggs J, Deng J, Ma Y, Lee H, et al. (2008) Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6: 1099-1105.
18. Zhang J, Li L, Kim SH, Hagerman AE, Lu J, (2009) Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm Res 26: 2066-2080.
19. Ellis LM, Hicklin DJ, (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
20. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
21. Wei D, Le X, Zheng L, Wang L, Frey JA, et al. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329.
22. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
23. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, et al. (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-36540.
24. Miles DH, Kokpol U, Zalkow LH, Steindel SJ, Nabors JB, (1974) Tumor inhibitors. I. Preliminary investigation of antitumor activity of sarracenia flava. J Pharm Sci 63: 613-615.
25. Kingston DG, Munjal RC, (1976) Plant anticancer agents. VIII. Constituents of Inga punctata. Lloydia 41: 499-500.
26. Trumbull ER, Bianchi E, Eckert DJ, Wiedhopf RM, Cole JR, (1976) Tumor inhibitory agents from Vauquelinia corymbosa (Rosaceae). J Pharm Sci 65: 1407-1408.
27. Kessler JH, Mullauer FB, de Roo GM, Medema JP, (2007) Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett 251: 132-145.
28. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, et al. (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25.
29. Rieber M, Strasberg RM, (1998) Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. DNA Cell Biol 17: 399-406.
30. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, et al. (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114: 935-940.
31. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, et al. (1997) Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956-4964.
32. Karna E, Szoka L, Palka JA, (2010) Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem 340: 15-20.
33. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, et al. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560.
34. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by Hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
35. Gariboldi MB, Ravizza R, Monti E, (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80: 455-462.
36. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, et al. (2009) Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 30: 1848-1856.
37. Park KY, Lee HJ, Jeong SJ, Kim HS, Kim SH, et al. (2010) 1,2,3,4,6-Penta-O-galloly-beta-D-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and signaling in LNCaP prostate cancer cells. Biol Pharm Bull 33: 1835-1840.
38. Kim SH, Ahn KS, Jeong SJ, Kwon TR, Jung JH, et al. (2011) Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells. Eur J Pharmacol 654: 10-16.
39. Choo EJ, Rhee YH, Jeong SJ, Lee HJ, Kim HS, et al. (2011) Anethole exerts antimetatstaic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull 34: 41-46.
40. Lee HJ, Kim SA, Lee HJ, Jeong SJ, Han I, et al. (2010) Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS One 5: e12358.